Cell Therapy Developer SBioMedics Raises 2 Billion Won in Paid-in Capital Increase... "For Operating Fund Procurement"

Esbiomedics, a KOSDAQ-listed cell therapy developer, announced on the 13th that it has decided to raise 2 billion KRW through a third-party allotment paid-in capital increase to secure operating funds and other expenses.

A total of 271,320 new common shares will be issued at a price of 25,800 KRW per share. The third-party allotment recipients include SYS Holdings (116,280 shares) and Dongkook Pharmaceutical (58,140 shares), among others.

The company stated that the purpose of the third-party allotment capital increase is "to achieve management objectives through operating funds and other funds (clinical trial costs)."

This content was produced with the assistance of AI translation services.